CXCL9 and cancer: In a phase I trial of intravenous Helixor® M in advanced cancer patients, treatment resulted in increased levels of CXCL9 and CXCL10, chemokines that mediate the recruitment of cytotoxic T and NK cells to solid tumors [43].